UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018742
Receipt number R000021685
Scientific Title Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with familial adenomatous polyposis -2
Date of disclosure of the study information 2015/08/21
Last modified on 2021/08/24 11:53:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with familial adenomatous polyposis -2

Acronym

Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with FAP -2 (J-FAPP Study 3-2)

Scientific Title

Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with familial adenomatous polyposis -2

Scientific Title:Acronym

Intervention trial for colorectal cancer prevention by endoscopic polypectomy in patients with FAP -2 (J-FAPP Study 3-2)

Region

Japan


Condition

Condition

Patients with familial adenomatous polyposis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the usefulness and safety of thorough endoscopic polypectomy in patients with FAP.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I,II


Assessment

Primary outcomes

Whether or not a patient needs surgery on the large intestine during the intervention period. It includes not only the development of a polyp that cannot be removed endoscopically or that of large intestinal cancer, but also cases where a patient wishes to undergo resection of the large intestine because of discomfort of endoscopic examination, and cases where emergency surgery is performed because of perforation occurred during endoscopic treatment.

Key secondary outcomes

Presence or absence of the development of adverse events (perforation, hemorrhage, death from large intestinal cancer, and death from other causes), colorectal cancer, intramucosal carcinoma, or a tumor that is difficult to treat endoscopically.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Maneuver

Interventions/Control_1

Colonic polyps will be thoroughly removed by periodic colonoscopy.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who have (or had) 100 or more adenomas in the large intestine and who refused to undergo surgery despite of being advised to do so, and who are 16 years or older (parental consent is required in patients younger than 20 years). Patients who have (or had) 100 or more adenomas in the large intestine and who had part of the large intestine resected by surgery but still have 10 cm or more of the large intestine, and who are 16 years or older (parental consent is required in patients younger than 20 years).

Key exclusion criteria

Patients who are considered by their attending physicians to be ineligible to participate in the study because they have a serious disease in other organs, or because they cannot discontinue antiplatelet drugs, or for other reasons.
Patients who are receiving anticancer drugs.
Patients with dense FAP in at least one-third of the large intestine.
Patients in whom strict follow-up is difficult.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Hideki
Middle name
Last name Ishikawa

Organization

Kyoto Prefectural University of Medicine

Division name

Department of Molecular-Targeting Prevention

Zip code

541-0042

Address

3-2-17-2F Imabashi, Chuo-ku, Osaka 541-0042, Japan

TEL

06-6202-5444

Email

cancer@gol.com


Public contact

Name of contact person

1st name Hideki
Middle name
Last name Ishikawa

Organization

Kyoto Prefectural University of Medicine

Division name

Department of Molecular-Targeting Prevention

Zip code

541-0042

Address

3-2-17-2F Imabashi, Chuo-ku, Osaka 541-0042, Japan

TEL

06-6202-5444

Homepage URL


Email

cancer@gol.com


Sponsor or person

Institute

Kyoto Prefectural University of Medicine

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto Prefectural University of Medicine

Address

602-8566 Kyoto-shi, Kamigyo-ku Kajii-cho, Kawaramachi-Hirokoji, JAPAN

Tel

private

Email

private


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

石川消化器内科(大阪府)
札幌医科大学附属病院(北海道)
愛知県がんセンター中央病院(愛知県)
国立がん研究センター中央病院(東京都)
兵庫医科大学病院(兵庫県)
徳島大学病院(徳島県)
広島大学病院(広島県)
石川県立中央病院(石川県)
大阪国際がんセンター(大阪府)
佐野病院(兵庫県)
栃木県立がんセンター(栃木県)
岩国医療センター(山口県)
四国がんセンター(愛媛県)
群馬中央病院(群馬県)
がん研有明病院(東京都)
国立がん研究センター東病院(千葉県)
近畿大学医学部附属病院(大阪府)
東邦大学医療センター大橋病院(東京都)
京都大学医学部附属病院(京都府)
埼玉医科大学総合医療センター(埼玉県)
守口敬仁会病院(大阪府)
産業医科大学病院(福岡県)
帯広厚生病院(北海道)
九州大学病院(福岡県)


Other administrative information

Date of disclosure of the study information

2015 Year 08 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2015 Year 08 Month 20 Day

Date of IRB

2015 Year 09 Month 03 Day

Anticipated trial start date

2015 Year 09 Month 14 Day

Last follow-up date

2026 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 08 Month 20 Day

Last modified on

2021 Year 08 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021685


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name